Pulse Biosciences Company Insiders

PLSE Stock  USD 19.63  1.84  10.34%   
Pulse Biosciences' insiders are aggressively buying. The analysis of insiders' sentiment of trading Pulse Biosciences stock suggests that all insiders are extremely bullish at this time. Pulse Biosciences employs about 56 people. The company is managed by 14 executives with a total tenure of roughly 131 years, averaging almost 9.0 years of service per executive, having 4.0 employees per reported executive.

Pulse Biosciences' Insider Buying Vs Selling

100

 
Selling
 
Buying

Latest Trades

2024-12-13Robert W DugganAcquired 55256 @ 17.18View
2024-12-11Robert W DugganAcquired 56054 @ 17.35View
2024-05-20Burke Thomas BarrettAcquired 10000 @ 8.56View
Monitoring Pulse Biosciences' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
  
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pulse Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
For information on how to trade Pulse Stock refer to our How to Trade Pulse Stock guide.

Pulse Biosciences' Workforce Through the Years

Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Pulse Biosciences' future performance. Based on our forecasts, it is anticipated that Pulse will maintain a workforce of about 60 employees by February 2025.
 
Covid

Pulse Biosciences Management Team Effectiveness

The company has return on total asset (ROA) of (0.3815) % which means that it has lost $0.3815 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7028) %, meaning that it created substantial loss on money invested by shareholders. Pulse Biosciences' management efficiency ratios could be used to measure how well Pulse Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. As of January 4, 2025, Return On Tangible Assets is expected to decline to -0.94. In addition to that, Return On Capital Employed is expected to decline to -1. At present, Pulse Biosciences' Debt To Assets are projected to increase slightly based on the last few years of reporting. The current year's Fixed Asset Turnover is expected to grow to 0.11, whereas Net Tangible Assets are forecasted to decline to about 26.1 M.
The current year's Common Stock Shares Outstanding is expected to grow to about 58 M, whereas Net Loss is projected to grow to (54.4 M).

Pulse Biosciences Workforce Comparison

Pulse Biosciences is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 22,266. Pulse Biosciences adds roughly 56.0 in number of employees claiming only tiny portion of equities under Health Care industry.

Pulse Biosciences Insider Trading History

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Pulse Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Pulse Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Pulse Biosciences insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Yuan Drop
 
Covid
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2024-12-01
3.0
6
2
 5,417,466 
 74,656 
2024-09-01
10.3333
31
3
 8,715,982 
 1,324 
2023-12-01
5.7143
40
7
 2,221,721 
 231,287 
2023-09-01
1.6
8
5
 635,467 
 135,467 
2023-06-01
3.5714
25
7
 17,207,061 
 269,377 
2021-06-01
12.0
12
1
 3,251,493 
 1,485 
2021-03-01
3.6667
11
3
 177,092 
 1,610 
2020-12-01
2.0
4
2
 411,096 
 9,070 
2019-06-01
5.5
11
2
 146,754 
 38,992 
2019-03-01
1.5
6
4
 52,303 
 86,159 
2018-06-01
6.0
6
1
 96,353 
 7,168 
2017-06-01
5.75
46
8
 1,574,778 
 100,000 
2017-03-01
6.0
12
2
 322,991 
 0.00 

Pulse Biosciences Notable Stakeholders

A Pulse Biosciences stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Pulse Biosciences often face trade-offs trying to please all of them. Pulse Biosciences' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Pulse Biosciences' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Kevin DanahyPresident CEOProfile
Burke BarrettCEO PresidentProfile
Robert DugganExecutive CoChairmanProfile
Darrin UeckerPrincipal CTOProfile
Patty PerlaVice ResourcesProfile
Sandra GardinerCFO AdminProfile
JD EsqGeneral SecretaryProfile
Gansevoort MDChief OfficerProfile
Niv MDChief SurgeryProfile
Richard NuccitelliChief OfficerProfile
Mitchell LevinsonChief DirectorProfile
Holly JDVP StrategyProfile
David DanitzSenior EngineeringProfile
Edison ManuelVice OperationsProfile

About Pulse Biosciences Management Performance

The success or failure of an entity such as Pulse Biosciences often depends on how effective the management is. Pulse Biosciences management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Pulse management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Pulse management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.89)(0.94)
Return On Capital Employed(0.96)(1.00)
Return On Assets(0.82)(0.86)
Return On Equity(0.86)(0.81)
Please note, the presentation of Pulse Biosciences' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Pulse Biosciences' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Pulse Biosciences' management manipulating its earnings.

Pulse Biosciences Workforce Analysis

Traditionally, organizations such as Pulse Biosciences use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Pulse Biosciences within its industry.

Pulse Biosciences Manpower Efficiency

Return on Pulse Biosciences Manpower

Revenue Per Employee-161
Revenue Per Executive-643
Net Loss Per Employee753.8K
Net Loss Per Executive3M
Working Capital Per Employee689.6K
Working Capital Per Executive2.8M

Complementary Tools for Pulse Stock analysis

When running Pulse Biosciences' price analysis, check to measure Pulse Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pulse Biosciences is operating at the current time. Most of Pulse Biosciences' value examination focuses on studying past and present price action to predict the probability of Pulse Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pulse Biosciences' price. Additionally, you may evaluate how the addition of Pulse Biosciences to your portfolios can decrease your overall portfolio volatility.
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules